Posted by Michael Wonder on 27 Feb 2024
BeiGene’s biologics license application for Tevimbra (tislelizumab) for first-line gastric or gastro-oesophageal junction cancers accepted by FDA
27 February 2024 - Application based on results from global Phase 3 RATIONALE-305 trial demonstrating Tevimbra plus chemotherapy significantly improved overall survival in advanced gastric/GEJ cancer.
BeiGene today announced that the US FDA has accepted a biologics license application for Tevimbra (tislelizumab), in combination with fluoropyrimidine- and platinum-containing chemotherapy, for the treatment of patients with locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma.
